Pfizer Inc. $PFE Shares Acquired by Huber Capital Management LLC

Key Points

• Huber Capital Management LLC increased its holdings in Pfizer Inc. by 17.4%, acquiring 85,000 shares to own a total of 573,288 shares, valued at approximately $14.5 million.
• Pfizer reported earnings of $0.78 per share, surpassing analysts' estimates, with revenues of $14.65 billion for the last quarter, marking a significant year-over-year increase of 10.3%.
• The company announced a quarterly dividend of $0.43 per share, with a dividend yield of 6.9%, to be paid on September 2nd, reflecting a payout ratio of 91.49%.

Huber Capital Management LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 17.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 573,288 shares of the biopharmaceutical company's stock after purchasing an additional 85,000 shares during the period. Pfizer accounts for approximately 2.7% of Huber Capital Management LLC's investment portfolio, making the stock its 11th biggest holding. Huber Capital Management LLC's holdings in Pfizer were worth $14,527,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Bessemer Group Inc. grew its holdings in shares of Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK grew its holdings in shares of Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Pfizer during the first quarter valued at $8,283,000. Alta Advisers Ltd grew its holdings in shares of Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after buying an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC grew its holdings in shares of Pfizer by 8.7% during the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after buying an additional 10,051 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.6%

PFE stock opened at $25.08 on Thursday. The company's 50-day simple moving average is $24.76 and its 200-day simple moving average is $24.40. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The firm has a market cap of $142.57 billion, a P/E ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company posted $0.60 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PFE shares. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wolfe Research boosted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Finally, Jefferies Financial Group upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer presently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.